Why Some Spider Veins Resist Microsclerotherapy: The Role of Vessel Size and When to Change Approach

Have you ever treated leg spider veins with flawless microsclerotherapy technique, only to find the vessels completely unchanged—or worse, fully returned—at the six-week review? In this video, Dr. Haroun Gajraj breaks down the frustrating clinical challenge of **spider vein resistance** to Microsclerotherapy. If your injection technique was sound, the sclerosant concentration was appropriate, and the vessels blanched perfectly, the problem isn't your skill—it's the vessel itself. We explore why standard CEAP C1 classifications fail to explain treatment resistance, how to use a simple 30-gauge needle as a visual caliper at the examination couch, and how to implement a size-based framework to determine when to stick with microsclerotherapy, when to order a duplex ultrasound, and when to switch to 4 MHz radiofrequency thermocoagulation (shortwave diathermy). 📝 READ THE COMPANION ARTICLE & EVIDENCE TABLES For the complete Ferrara subclassification breakdown, comprehensive evidence tables, and deep-dive duplex screening protocols, read the full article here: 🔗 **[https://www.veincare.academy/blog/resistant-spider-veins-vessel-size-microsclerotherapy]** ⏱️ TIMESTAMPS 00:00 — Introduction: The Frustrating Problem of Spider Vein Resistance 02:04 — Let's Start with the Clinical Problem: When Microsclerotherapy Doesn't Work 03:12 — The Instinctive Technical Response (And Why It’s Often Wrong) 04:25 — Introducing a Framework Based on Vessel Size 04:59 — Why the CEAP C1 Classification Can't Explain Resistance 06:53 — Mapping the Size Spectrum: From Ultra-Fine to Reticular Veins 08:31 — The Published Evidence: Trelles (2020), Weiss (1999) & Goldman (2006) 11:34 — Classifying Your Patient: Responsive vs. Resistant Lesions 12:56 — The Ferrara & Ferrara (2013) Subclassification Framework 13:50 — Type A Lesions: Hemodynamic Resistance & Reflux 14:31 — Type B Lesions: Responsive Clusters 14:52 — Type C Lesions: Biological Resistance in Ultra-Fine Vessels 15:52 — Applying Heat Energy: 4 MHz Radiofrequency Thermocoagulation 18:04 — Clinical Trial Evidence for Adjuvant Thermocoagulation (Dicken et al., 2021) 19:39 — On-Couch Assessment: The 30-Gauge Needle Test 21:33 — Investigating the Hemodynamic Source (Societal Scanning Guidelines) 23:31 — A Different Perspective on Early Recurrence 24:58 — Summary & Key Clinical Takeaways to Take Back to Your Clinic 🧠 **KEY CLINICAL TAKEAWAYS FROM THIS VIDEO** CEAP C1 is Too Broad: Lumping 0.2mm intradermal telangiectasias and 2.5mm reticular feeder veins into a single C1 category leads to an undifferentiated treatment approach. Diameter must be your central organizing principle. The 1mm Threshold Matters: Randomized data (Trelles et al., 2020) proves that below 1mm, injection becomes progressively less reliable, while laser and thermal modalities excel. Above 1mm, polidocanol sclerotherapy remains the gold standard. The Ferrara Subclassification Protocol: Type A (Hemodynamic): Driven by an underlying refluxing feeder or perforator. They require Duplex Ultrasound investigation, not a change in surface modality. Type B (Responsive): Isolated clusters larger than 0.2mm without deep reflux. Highly responsive to standard microsclerotherapy. Type C (Biological Resistance): Isolated telangiectasias at or below 0.2mm. Extremely difficult to cannulate with insufficient luminal volume for sclerosant contact time. These are best treated with thermocoagulation. The 30-Gauge Needle Visual Comparator: A standard 30G needle has an outer diameter of ~0.3mm. If the resistant spider vein is visibly narrower than the needle wall, it sits in the size band where thermocoagulation is clinically indicated over repeated injections. Recurrence is a Signal: When spider veins rapidly return in the exact same distribution, it isn't a technical failure—it's a definitive clinical sign of an untreated hemodynamic source refilling the surface vessels. 💬 JOIN THE CONVERSATION Are you incorporating 4 MHz radiofrequency thermocoagulation or lasers alongside your microsclerotherapy? How do you manage patients with ultra-fine, resistant Type C vessels in your clinic? Let’s discuss in the comments below! If you found this clinical breakdown valuable, please Like, Share, and Subscribe to help support the channel and ensure you don't miss the next video. 📱 CONNECT WITH DR. HAROUN GAJRAJ **Website**: **https://www.veincare.academy/blog** **Disclaimer: Health professionals should only provide treatments for which they have proper training and knowledge. This video serves only as a source of additional information to healthcare professionals and the public** **LinkedIn**: **https://www.linkedin.com/in/dr-haroun-gajraj/** #Phlebology #Microsclerotherapy #SpiderVeins #VascularSurgery #Thermocoagulation #ShortwaveDiathermy #Sclerotherapy #MedicalEducation #CEAPC1